184 related articles for article (PubMed ID: 36509836)
1. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis M; Soree B; Jama WOM; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Rongen GA; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Risselada A
Eur J Hum Genet; 2023 Dec; 31(12):1364-1370. PubMed ID: 36509836
[TBL] [Abstract][Full Text] [Related]
2. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw D; van Westrhenen R; Deneer VHM; van der Weide J
Eur J Hum Genet; 2024 Mar; 32(3):278-285. PubMed ID: 37002327
[TBL] [Abstract][Full Text] [Related]
3. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
4. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
Brown JT
Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
[TBL] [Abstract][Full Text] [Related]
5. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL; Nijenhuis M; Soree B; Guchelaar HJ; Swen JJ; van Schaik RHN; Weide JV; Rongen GAPJM; Buunk AM; de Boer-Veger NJ; Houwink EJF; van Westrhenen R; Wilffert B; Deneer VHM; Mulder H
Eur J Hum Genet; 2022 Oct; 30(10):1114-1120. PubMed ID: 34782755
[TBL] [Abstract][Full Text] [Related]
6. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Hulshof EC; Deenen MJ; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Touw DJ; van der Weide J; van Westrhenen R; Deneer VHM; Guchelaar HJ; Swen JJ
Eur J Hum Genet; 2023 Sep; 31(9):982-987. PubMed ID: 36443464
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes.
Kim SH; Byeon JY; Kim YH; Lee CM; Lee YJ; Jang CG; Lee SY
Sci Rep; 2018 Aug; 8(1):12405. PubMed ID: 30120390
[TBL] [Abstract][Full Text] [Related]
8. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs.
Manson LEN; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Risselada A; Rongen GAPJM; van Schaik RHN; Swen JJ; Touw DJ; van Westrhenen R; Deneer VHM; Guchelaar HJ
Eur J Hum Genet; 2024 Apr; ():. PubMed ID: 38570725
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
10. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
11. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group.
Caudle KE; Sangkuhl K; Whirl-Carrillo M; Swen JJ; Haidar CE; Klein TE; Gammal RS; Relling MV; Scott SA; Hertz DL; Guchelaar HJ; Gaedigk A
Clin Transl Sci; 2020 Jan; 13(1):116-124. PubMed ID: 31647186
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
13. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
14. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
[TBL] [Abstract][Full Text] [Related]
15. Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.
van der Pol KH; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Risselada A; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Houwink EJF; Rongen GA
Eur J Hum Genet; 2024 Feb; 32(2):155-162. PubMed ID: 36056234
[TBL] [Abstract][Full Text] [Related]
16. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
[TBL] [Abstract][Full Text] [Related]
17. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study.
Jukic MM; Smith RL; Haslemo T; Molden E; Ingelman-Sundberg M
Lancet Psychiatry; 2019 May; 6(5):418-426. PubMed ID: 31000417
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]